| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/26/2013 | US8383614 Hypercholestrolemia and tendinous injuries |
| 02/26/2013 | US8383613 Methods for the treatment of cancer |
| 02/26/2013 | US8383612 Microcrystalline oral suspension; mycocardial infarction; may include diuretic, vasodilator, digitalis, ACE-inhibitor; antagonist of angiotensin-II, aldosterone or endothelin receptors; xanthin oxidase inhibitor; bile acid resin; beta blocker, statin, anticholesterol agent, nicotinic or fibric acid |
| 02/26/2013 | US8383611 Ciclesonide containing aqueous pharmaceutical composition |
| 02/26/2013 | US8383610 Salts and polymorphs of 9-(2,2-dimethylpropyl-aminomethyl) minocycline |
| 02/26/2013 | US8383609 Phosphorus containing heterocyclic compounds, sugar analogues, and compositions having anti-cancer activity containing the same |
| 02/26/2013 | US8383608 Imidazolidine compounds as androgen receptor modulators |
| 02/26/2013 | US8383607 Perifosine and capecitabine as a combined treatment for cancer |
| 02/26/2013 | US8383606 Sulfoalkyl ether cyclodextrin compositions |
| 02/26/2013 | US8383605 Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals |
| 02/26/2013 | US8383602 Use of TRIM72 as a target for muscle and heart enhancer |
| 02/26/2013 | US8383597 G proteins in tumor growth and angiogenesis |
| 02/26/2013 | US8383596 Antibacterial aminoglycoside analogs |
| 02/26/2013 | US8383579 Method for customized dispensing of variable dose drug combination products for individualizing of therapies |
| 02/26/2013 | US8383371 Nucleic acid construct containing a nucleic acid derived from the genome of hepatitis C virus (HCV) of genotype 2a, and a cell having such nucleic acid construct introduced therein |
| 02/26/2013 | US8383178 Treating fish oils with certain amines/amides to reduce oxidation |
| 02/26/2013 | US8383164 Antiviral composition and method for using the same |
| 02/26/2013 | US8383158 Methods and compositions to treat myocardial conditions |
| 02/26/2013 | US8383156 Coating for a medical device having an anti-thrombotic conjugate |
| 02/26/2013 | US8383155 Swellable dosage form comprising gellan gum |
| 02/26/2013 | US8383154 Swellable dosage form comprising gellan gum |
| 02/26/2013 | US8383153 Poly(amidoamine) oligomer hydrogel for drug delivery and drug carrier using the same |
| 02/26/2013 | US8383152 Pharmaceutical dosage form |
| 02/26/2013 | US8383149 High enhancer-loading polyacrylate formulation for transdermal applications |
| 02/26/2013 | US8383139 Thiadiazolyloxyphenylamidines and use thereof as fungicides |
| 02/26/2013 | US8383127 Polysaccharide extract of Lentinus and pharmaceutical, cosmetic or nutraceutical compositions comprising such an extract |
| 02/26/2013 | US8383120 Concomitant treatment of rheumatoid arthritis with anti-TNF-alpha antibodies and methotrexate |
| 02/26/2013 | US8383100 Method to treat and prevent skin diseases with Porifera-based therapeutic compositions treating and preventing skin diseases |
| 02/26/2013 | US8383093 Subcutaneous delivery of poly(oxazoline) conjugates |
| 02/26/2013 | US8383092 Bioadhesive constructs |
| 02/26/2013 | US8383091 Biodegradable polyacetals for in vivo polynucleotide delivery |
| 02/26/2013 | US8383086 Nicotinamide riboside kinase compositions and methods for using the same |
| 02/26/2013 | US8382698 Systems and methods for improving image-guided tissue ablation |
| 02/26/2013 | CA2727899C Delayed release rasagiline formulation |
| 02/26/2013 | CA2655668C Aziridinyl-epothilone compounds |
| 02/26/2013 | CA2617659C Use of hydroxybenzoic acid esters and analogues for the manufacture of a medicament for the prevention and treatment of virus infection |
| 02/26/2013 | CA2608539C Process for preparing 3.alpha.(.beta.)-7.alpha.(.beta.)-dihydroxy-6.alpha.(.beta.)-alkyl-5.beta.-cholanic acid |
| 02/26/2013 | CA2608468C Tri-, tetra-substituted-3-aminopyrrolidine derivative |
| 02/26/2013 | CA2580659C Corticosteroid having low systemic absorption |
| 02/26/2013 | CA2579784C Topical compositions containing phosphorylated polyphenols |
| 02/26/2013 | CA2572544C Modified pyrimidine glucocorticoid receptor modulators |
| 02/26/2013 | CA2571527C Piperazinediones as oxytocin receptor antagonists |
| 02/26/2013 | CA2564546C Aerosolized fosfomycin/aminoglycoside combination for the treatment of bacterial respiratory infections |
| 02/26/2013 | CA2551780C The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and copd |
| 02/26/2013 | CA2550848C Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases |
| 02/26/2013 | CA2543497C Controlled release analgesic suspensions |
| 02/26/2013 | CA2542076C Substituted tricyclic compounds as protein kinase inhibitors |
| 02/26/2013 | CA2541584C Composition for promoting collagen production comprising a purine nucleic acid-related substance and a pyrimidine nucleic acid-related substance |
| 02/26/2013 | CA2537336C Multi-arm polymer prodrugs |
| 02/26/2013 | CA2534682C Capped pyrazinoylguanidine sodium channel blockers |
| 02/26/2013 | CA2532730C Antimicrobial compositions containing synergistic combinations of quaternary ammonium compounds and essential oils and/or constituents thereof |
| 02/26/2013 | CA2523426C Aza spiro alkane derivatives as inhibitors of metalloproteases |
| 02/26/2013 | CA2481916C A therapeutic agent for impaired gastric accommodation |
| 02/26/2013 | CA2452401C Process for producing fat comprising triglyceride containing highly unsaturated fatty acid |
| 02/26/2013 | CA2430115C Recombinant rsv virus expression systems and vaccines |
| 02/26/2013 | CA2358570C Protonated/acidified nucleic acids and methods of use |
| 02/21/2013 | WO2013026025A1 Cyclohexyl azetidine derivatives as jak inhibitors |
| 02/21/2013 | WO2013025992A1 Therapeutic methods |
| 02/21/2013 | WO2013025984A2 Cannabinoid receptor treatments |
| 02/21/2013 | WO2013025975A1 Combination treatments for hepatitis c |
| 02/21/2013 | WO2013025958A1 Amino quinazolines as kinase inhibitors |
| 02/21/2013 | WO2013025951A1 Fine dry particulate adenosine compositions and topical formulations including the same |
| 02/21/2013 | WO2013025939A2 Compounds and methods for treating cancer by inhibiting the urokinase receptor |
| 02/21/2013 | WO2013025936A1 Detection and treatment of metastatic disease |
| 02/21/2013 | WO2013025918A2 Methods useful in the prevention of hypoxic injury |
| 02/21/2013 | WO2013025883A1 Heteroaryl sodium channel inhibitors |
| 02/21/2013 | WO2013025882A2 Tricyclic compounds as anticancer agents |
| 02/21/2013 | WO2013025858A1 5-benzyl-n-phenyethyl-1,3,4-oxadiazole-2-carboxamide derivatives |
| 02/21/2013 | WO2013025840A1 Methods for preserving photoreceptor cell viability following retinal detachment |
| 02/21/2013 | WO2013025795A1 5-fluoro-4-imino-3-(substituted)-3,4-dihydropyrimidin-2-(1h)-one derivatives |
| 02/21/2013 | WO2013025790A2 No- and h2s- releasing compounds |
| 02/21/2013 | WO2013025788A1 Tenofovir alafenamide hemifumarate |
| 02/21/2013 | WO2013025775A1 Process for manufacturing hmb and salts thereof |
| 02/21/2013 | WO2013025733A1 Lysophosphatidic acid receptor antagonists |
| 02/21/2013 | WO2013025628A1 Janus kinase inhibitor compounds and methods |
| 02/21/2013 | WO2013025607A1 Methods of treating amyloidoses with vitamin b12 and test for detecting amyloid-beta peptides |
| 02/21/2013 | WO2013025584A1 Inhibitors of human immunodeficiency virus replication |
| 02/21/2013 | WO2013025564A2 Furfural production from biomass |
| 02/21/2013 | WO2013025560A1 Sweet flavor modifier |
| 02/21/2013 | WO2013025508A1 Quinazolinone analogs and use of quinazolinone analogs for treating or preventing certain viral infections |
| 02/21/2013 | WO2013025490A1 Compositions and methods for treatment of autoimmune and other diseases |
| 02/21/2013 | WO2013025484A1 Polyphenol analogs to treat ischemia |
| 02/21/2013 | WO2013025452A1 Selective glycosidase inhibitors and uses thereof |
| 02/21/2013 | WO2013025442A2 Concentrated felbamate formulations for parenteral administration |
| 02/21/2013 | WO2013025425A1 Soluble guanylate cyclase activators |
| 02/21/2013 | WO2013025424A1 A Novel 1,2,3,4-Tetrahydroquinoline Derivative Useful for the Treatment of Diabetes |
| 02/21/2013 | WO2013025418A1 Delivery system for specifically targeting cancer cells and method of use thereof |
| 02/21/2013 | WO2013025399A1 Methods for ameliorating symptoms or conditions caused by stress |
| 02/21/2013 | WO2013025337A1 Cyclodextrin-based polymers for therapeutic delivery |
| 02/21/2013 | WO2013025203A1 Resolution of tetrahydrofolic acid derivatives |
| 02/21/2013 | WO2013025180A1 [60]fullerene and its use to maintain good health and to prolong the expected lifespan of mammals |
| 02/21/2013 | WO2013025112A1 Combination of sodium butyrate and organic acids for preventing and reducing diarrhoeas |
| 02/21/2013 | WO2013025074A2 Anticancer or antioxidant composition containing quamoclit pennata extract or compound derived from quamoclit pennata extract |
| 02/21/2013 | WO2013025064A2 Anti-cancer composition comprising wnt decoy receptors |
| 02/21/2013 | WO2013024968A1 Novel compound isolated from quamoclit, and composition for preventing or treating diabetes containing the compound as an active ingredient |
| 02/21/2013 | WO2013024898A1 Heterocyclic derivative and pharmaceutical drug |
| 02/21/2013 | WO2013024895A1 Tricyclic heterocyclic compounds and jak inhibitors |
| 02/21/2013 | WO2013024865A1 Antitumor agent and therapeutic effect prediction method for patients with kras-mutated colorectal cancer |
| 02/21/2013 | WO2013024763A1 Production method for nucleic acid aptamer |
| 02/21/2013 | WO2013024663A1 Composition containing s-adenosyl-l-methionine with excellent storage stability |